{"title":"Development and in vitro Characterization of Self-nanoemulsifying Drug Delivery Systems of Valsartan","authors":"P. S. Rajinikanth, Yeoh Suyu, Sanjay Garg","volume":72,"journal":"International Journal of Pharmacological and Pharmaceutical Sciences","pagesStart":733,"pagesEnd":739,"ISSN":"1307-6892","URL":"https:\/\/publications.waset.org\/pdf\/4400","abstract":"
The present study is aim to prepare and evaluate the selfnanoemulsifying drug delivery (SNEDDS) system of a poorly water soluble drug valsartan in order to achieve a better dissolution rate which would further help in enhancing oral bioavailability. The present research work describes a SNEDDS of valsartan using labrafil M 1944 CS, Tween 80 and Transcutol HP. The pseudoternary phase diagrams with presence and absence of drug were plotted to check for the emulsification range and also to evaluate the effect of valsartan on the emulsification behavior of the phases. The mixtures consisting of oil (labrafil M 1944 CS) with surfactant (tween 80), co-surfactant (Transcutol HP) were found to be optimum formulations. Prepared formulations were evaluated for its particle size distribution, nanoemulsifying properties, robustness to dilution, self emulsication time, turbidity measurement, drug content and invitro dissolution. The optimized formulations are further evaluated for heating cooling cycle, centrifugation studies, freeze thaw cycling, particle size distribution and zeta potential were carried out to confirm the stability of the formed SNEDDS formulations. The prepared formulation revealed t a significant improvement in terms of the drug solubility as compared with marketed tablet and pure drug.<\/p>\r\n","references":"[1] Lipinski C: Poor aqueous solubility - an industry wide problem in drug\r\ndiscovery.\r\n(http:\/\/americanpharmaceuticalreview.com\/ViewArticle.aspx?ContentID\r\n=142)\r\n[2] Di L, Kerns EH: Optimizing the physicochemical properties of clinical\r\ncandidates during drug discovery.\r\n(http:\/\/mediaserver.aaps.org\/meetings\/webinars\/ppb-9\/ppb-9.pdf)\r\n[3] Stegemann S, Leveiller F, Franchi D, Jong HD, Linden H: When poor\r\nsolubility becomes an issue: From early stage to proof of concept.\r\n(http:\/\/capsugel.com\/media\/library\/when-poor-solubility-becomes-anissue-\r\nfrom-early-stage-to-proof-of-concept.pdf)\r\n[4] Product Leaftlet of Diovan. New Jersey: Norvartis; 2011 Apr\r\n[5] Siddiqui N et al: Pharmacacological and Pharmaceutical Profile of\r\nValsartan: A Review. Journal of Applied Pharmaceutical Science 2011;\r\n01(04): 12-9\r\n[6] Saydam M, Takka S: Bioavailability File: Valsartan. FABAD J. Pharm.\r\nSci. 2007; 32: 185 - 196.\r\n[7] Venkates KK, Arunkumar N, Verma PRP, Rani C: Preparation and in\r\nvitro characterization of valsartan solid dispersion using skimmed milk\r\npowder as carrier. IJPRIF. 2009, 1(3):431-7.\r\n[8] Mahapatra AK, Murthy PN, Biswal S, Mahapatra APK, Pradhan SP:\r\nDissolution enhancement and physicochemical characterization of\r\nvalsartan in solid dispersions with \u00b6\u00c7\u00f6\u00fc-CD, HP \u00b6\u00c7\u00f6\u00fc-CD and PVP K-30.\r\nDissolution Technologies 2011, 39-35.\r\n[9] Dixit AR, Rajput SJ, Patel SG: Preparation and bioavailability\r\nassessment of SMEDDS containing valsartan. AAPS 2010, 11(1):314-21\r\n[10] Jain CP, Naruka PS: Formulation and evaluation of fast dissolving\r\ntablets of valsartan. IJPS 2009, 219-26.\r\n[11] Nielsen FS, Petersen KB, M\u251c\u255dllertz A: Bioavailability of probucol from\r\nlipid and surfactant based formulations in minipigs: influence of droplet\r\nsize and dietary state. Eur J Pharm Biopharm 2008, 69:553-62.\r\n[12] Kumar GP, Rambhau D, Aapte SS: Oral bioavailability enhancement of\r\ncarbamazepine in healthy human volunteers. J Pharm Research 2011,\r\n4(2): 361-5.\r\n[13] Taha EI, Al-Saidan S, Samy AM, Khan MA: Preparation and in vitro\r\ncharacterization of self-nanoemulsified drug delivery system (SNEDDS)\r\nof all-trans-retinol acetate. I J Pharm. 2004, 285(2004):109-19.\r\n[14] Patel AR, Vavia PR: Preparation and in vivo evaluation of SMEDDS\r\n(Self-Microemulsifying Drug Delivery System) containing fenofibrate.\r\nAAPS 2007, 9(3):344-52\r\n[15] Shafiq-un-Nabi S et al: Formulation Development and Optimization\r\nUsing Nanoemulsion Technique: A Technical Note. AAPS Pharm. Sci.\r\nTech. 2007, 8(2):28\r\n[16] Mahmood EA, Bendas ER, Mohamed MI: Preparation and evaluation of\r\nself-nanoemulsifying tablets of carvedilol. AAPS 2009, 10(1):9192-7.\r\n[17] Kassem AA, Marzouk MA, Ammar AA, Elosaily GH: Preparation and\r\nin vitro evaluation of self-nanoemulsifying drug delivery systems\r\n(SNEDDS) containing clotrimazole. Drug Discovery and Therapeutics\r\n2010, 4(5):373-9.\r\n[18] Jeevana JB, Sreelakshmi K: Design and evaluation of selfnanoemulsifying\r\ndrug delivery system of flutamide. J Young Pharm.\r\n2011, 3(1):4-8.\r\n[19] Gupta AK et al: Preparation and in-vitro evaluation of self-emulsifying\r\ndrug delivery system of antihypertensive drug valsartan. International\r\nJournal of Pharmaceutics and Live Sciences March 2011, 2(3): 633 -\r\n639.\r\n[20] Patel J, Kevin G, Patel A, Raval M, Sheth N: Design and development of\r\na self-nanoemulsifying drug delivery system for telmisartan for oral\r\ndelivery. IJPI 2011, 1(2):112-8.\r\n[21] Date AA, Desai N, Dixit R, Nagarsenker M: Self-nanoemulsifying Drug\r\nDelivery Systems: Formulation Insights, Applications and Advances.\r\nNanomedicine 2010, 5(10).\r\n[22] Pouton CW: Formulation of poorly water-soluble drugs for oral\r\nadministration: Physicochemical and physiological issues and the lipid\r\nformulation classification system. Eur J Pharm Sci. 2006, 29:278-87\r\n[23] Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM:\r\nNanoemulsions: Formation, structure and physical properties. J. Phys.\r\n2006, 18(2006): R635-666.\r\n[24] Zetasizer Nano series technical notes.\r\n(http:\/\/www.nbtc.cornell.edu\/facilities\/downloads\/Zeta%20potential%20\r\n-%20An%20introduction%20in%2030%20minutes.pdf)\r\n[25] Selection of emulsifiers. In Emulsion Science and Technology: A\r\nGeneral Introduction. Edited by Tadros TF. UK: Wiley-VCH; 2009:25.\r\n[26] Parambi DGT, Mathew M, Ganesan V: A validated stability indicating\r\nHPLC method for the determination of valsartan in tablet dosage forms.\r\nJournal of Applied Pharmaceutical Science 2011, 01(04): 97-9.","publisher":"World Academy of Science, Engineering and Technology","index":"Open Science Index 72, 2012"}